Platelet-rich plasma (PRP) and stromal vascular fraction (SVF) cells are clinically proven to aid in cellular regeneration and accelerate wound healing. The healing effect can be measured by epidermal growth factor (EGF) levels. This study aims to determine the effect of a combination of PRP and SVF injections on EGF levels during the healing of full-thickness burns in Wistar rats.
View Article and Find Full Text PDFThe previous study on the injection of SVFs in combination with PRP showed positive effect on the healing of deep dermal burns. We now seek to understand the effect on full thickness burns, as assessed by changes in serum FGF2, IGF1, epithelialization, and fibroblast count. Forty-eight Wistar rats were randomly divided into four groups: (1) rats with full thickness burns given a local injection of combined SVFs and PRP; (2) rats with burns given topical Vaseline; (3) rats with burns given a local injection of placebo; and (4) rats without burns.
View Article and Find Full Text PDFOur previous study on how the combination of stromal vascular fraction cells (SVFs) and platelet-rich plasma (PRP) affect deep dermal burn healing showed promising results. In this study, we assessed the effect on full-thickness burns by evaluating FGF7 serum level and capillary count. Forty-eight Wistar rats were divided into four major groups: (1) locally injected with combined SVFs and PRP; (2) topically applied Vaseline; (3) locally injected with placebo; (4) and rats without burns.
View Article and Find Full Text PDFThe combination of platelet-rich plasma (PRP) and stromal vascular fraction cells (SVFs) was beneficial in accelerating wound healing. This study aims to assess the effect of this combination in balancing the inflammatory process to accelerate burn healing. Thirty eligible Wistar rats were used in this study to establish a deep dermal degree burn wound model.
View Article and Find Full Text PDFBackground: Due to their immunomodulatory properties, mesenchymal stem cells (MSCs) have been proposed to have therapeutic potential to improve clinical outcomes in COVID-19. However, the safety and efficacy profile of MSC infusion therapy in patients with non-severe COVID-19 infection has not been completely established; there is, in particular, a substantial void in the literature on dose-dependent studies of MSC infusion in patients with low clinical risk COVID-19 infection.
Methods: This phase 1 double-blind, placebo-controlled, randomized clinical trial examines the safety, feasibility, and tolerability of 2 doses (high and low) of DW-MSC in patients with low clinical risk COVID-19.